My 10 Top Stocks to Buy to Start the New Year Off Right
But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...
CNBC on MSN23d
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions – NBC Los Angeles
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
As the New Year begins, the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) is urging the public to avoid ...
AOL20d
What is Compounded Tirzepatide? Here's What You Need to Know
Compounded tirzepatide isn’t FDA-approved. This means there’s no guarantee it’s safe or effective. If you’re considering it, go to a safe source. Just because you can buy tirzepatide ...
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...
Zacks.com on MSN7d
LLY Falls Around 14% in 3 Months: How to Play the Stock
Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...
Seeking Alpha28d
Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook
Eli Lilly's diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide, support a "buy" rating for long-term investors despite current valuation metrics.